ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 298 for:    Recruiting, Not yet recruiting, Available Studies | "Adenoma"

LCI (Linked Color Imaging) for Adenoma Detection in the Right Colon

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03279783
Recruitment Status : Recruiting
First Posted : September 12, 2017
Last Update Posted : September 12, 2017
Sponsor:
Information provided by (Responsible Party):
Franco Radaelli, Valduce Hospital

Brief Summary:

Although colonoscopy with polypectomy can prevent up to 80% of colorectal cancers, a significant adenoma miss rate still exists, particularly in the right colon. Optimizing the detection of adenomas and sessile serrated lesions in the right colon is crucial to increase the effectiveness of colonoscopy in colorectal cancer prevention.

Last generation Fuji videocolonscopes incorporates the Linked Color Imaging (LCI), a recently developed technology that differentiates the red colour spectrum more effectively than White Light imaging thanks to its optimal pre-process composition of light spectrum and advanced signal processing. The increased colour contrast results in more accurate delineation of abnormal inflammatory or neoplastic findings of colonic mucosa. Preliminary data suggest that LCI may be improve the detection of neoplastic lesion of colon.

The investigators performe a tandem prospective study to compare the right colon adenoma miss rates of LCI colonoscopy with those of conventional white light colonoscopy.

Therefore participants scheduled for colonoscopy for the assessment of symptoms or for colorectal cancer screening/surveillance receive the examination of the right colon twice, in a back to back fashion, with standard white light (WL) and with LCI. Patients are randomly assigned (1:1), via computer-generated randomisation with block size of 20, to which procedure is done first. The endoscopist are masked to group allocation until immediately before the cecum is reached. Examinations are performed with Fuji videocolonscopes series 700 (EC-760R, EC-760ZP).


Condition or disease Intervention/treatment Phase
Adenoma Colon Polyp Device: LCI (Linked color imaging) Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 752 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Participants scheduled for colonoscopy for the assessment of symptoms or for colorectal cancer screening/surveillance receive the examination of the right colon twice, in a back-to-back fashion, with standard white light (WL) and with LCI (Linked Color Imaging). Patients are randomly assigned (1:1), via computer-generated randomisation with block size of 20, to which procedure is done first.
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: LCI (Linked Color Imaging) for Adenoma Detection in the Right Colon
Actual Study Start Date : July 1, 2017
Estimated Primary Completion Date : December 1, 2017
Estimated Study Completion Date : December 30, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: WLI (White light Imaging)
Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
Active Comparator: LCI (Linked Color Imaging)
Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
Device: LCI (Linked color imaging)
Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)




Primary Outcome Measures :
  1. Right colon adenoma miss rate [ Time Frame: One year ]
    Number of adenomas identified during the second right coloninspection/ overall number of adenomas identified during the first and the second right colon inspection


Secondary Outcome Measures :
  1. Right colon advanced adenomas (size>1 cm and/or high grade displasia and/or villous component) miss rate [ Time Frame: One year ]
    Number of advanced adenomas identified during the second right coloninspection/ overall number of advanced adenomas identified during the first and the second right colon inspection

  2. Right colon sessile serrated lesions miss rate [ Time Frame: One year ]
    Number of sessile serrated lesions identified during the second right coloninspection/ overall number of sessile serrated lesions identified during the first and the second right colon inspection



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all outpatients referred for colonoscopy

Exclusion Criteria:

  • inadequatete bowel preparation (Boston Bowel Preparation Scale (BBPS) < 2 in one colonic segment)
  • previous colonic resection
  • inflammatory bowel disease
  • ereditary polyposic syndromes
  • patients on antithrombotics precluding polyp recetion
  • absence of informed consent
  • inpatients or patients undergoing urgent colonscopy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03279783


Locations
Italy
Gastroenterology Unit, Valduce Hospital Recruiting
Como, Italy, 22100
Contact: Franco Radaelli, MD    0039031324145    francoradaelli01@gmail.com   
Sponsors and Collaborators
Valduce Hospital

Responsible Party: Franco Radaelli, Head of Endoscopy Unit, Valduce Hospital
ClinicalTrials.gov Identifier: NCT03279783     History of Changes
Other Study ID Numbers: 341/2017
First Posted: September 12, 2017    Key Record Dates
Last Update Posted: September 12, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms